CA - Curaleaf: Wild Divide Between Wall Street And SA Analysts Sentiments
2024-03-11 11:24:10 ET
Summary
- Divergent views on Curaleaf between SA Analysts (sell) and Wall Street (strong buy) amid recent stock correction.
- Curaleaf shows strong financial results in 2023, leading in revenue among MSOs.
- The over-excitement on Curaleaf's TSX debut as well as its international exposure may have been overshadowed by recent increased likelihood of rescheduling cannabis in the U.S.
- Recent sharper stock price correction for Curaleaf compared to peers presents a window of opportunities for investors.
While other businesses may have a fairly consistent view and rating between SA Analysts and Wall Street Analysts, Curaleaf Holdings, Inc. (CURA:CA) (CURLF) ("Curaleaf") has somehow been treated vastly different....
Curaleaf: Wild Divide Between Wall Street And SA Analysts Sentiments